Carvedilol reduces myocardial no-reflow by decreasing endothelin-1 via activation of the ATP-sensitive K+ channel

Perfusion

Volumn 23, Issue 2, 2008, Pages 111-115

  Zhao, J L ^a   Yang, Yue Jin ^a   Pei, W D ^a   Sun, Y H ^a   Zhai, M ^a   Liu, Y X ^a   Gao, R L ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Acute myocardial infarction; Carvedilol; Reperfusion

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CARVEDILOL; ENDOTHELIN 1; GLIBENCLAMIDE; SONOVUE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE NECROSIS; HEART MUSCLE PERFUSION; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SWINE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARBAZOLES; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; GLYBURIDE; HYPOGLYCEMIC AGENTS; KATP CHANNELS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; POTASSIUM CHANNEL BLOCKERS; PROPANOLAMINES; SWINE; SWINE, MINIATURE;

EID: 61549142982     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659108094628     Document Type: Article

References (20)

1. Kelly RV Cohen MG Runge MS. et al. The no-reflow phenomenon in coronary arteries. J Thromb Haemostasis 2004; 2: 1903-1907.
2. Wu KC Zerhouni EA Judd RM. et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765-772.
3. Swinburn JM Lahiri A Senior R. Intravenous myocardial contrast echocardiography predicts recovery of dysynergic myocardium early after acute myocardial infarction. J Am Coll Cardiol 2001; 38: 19-25.
4. Reffelmann T Kloner RA. The "no-reflow" phenomenon: Basic science and clinical correlates. Heart 2002; 87: 162-168.
5. Zhao JL Yang YJ; You SJ;. et al. Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Int J Cardiol 2006 Jul 3; [Epub ahead of print]
6. Kloner RA Ganote CE Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-1508.
7. Wainstein MV; Goncalves SC; Zago AJ;. Plasma endothelin-1 levels after coronary stenting in humans. Am J Cardiol 2003, 15; 92: 1211-1214.
8. Galatius S Wroblewski H Sorensen VB. Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: Different stimuli for release before and after heart transplantation. Am Heart J 1999; 137(3): 549-554.
9. Gande S Miura T Miki T Ichikawa Y Shimamoto KK. (ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 2002; 40: 1339-1346.
10. Chen XC Zhang XM Luo NS Fang C Liu YM Wu W. Effects of endothelin receptor A antagonist FR139317 on rats with congestive heart failure. Acta Pharmacol Sin. 2001; 22: 896-900.
11. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
12. Saxenhofer H Morger D Weidmann P. et al. Modulation of noradrenergic but not angiotensinergic blood pressure control by beta-blockade with carteolol. J Hypertens 1991; 9: 1049-1056.
13. Silke B Verma SP Hussain M. et al. Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris. Br J Clin Pharmacol 1983; 16: 529-535.
14. Packer M Coats AJ Fowler MB. et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001; 344: 1651-1658.
15. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
16. Manciet LH Poole DC McDonagh PF. et al. Microvascular compression during myocardial ischemia: Mechanistic basis for no-reflow phenomenon. Am J Physiol 1994; 266: H1541-H1550.
17. Gavin JB Thomson RW Humphrey SM. et al. Changes in vascular morphology associated with the no-reflow phenomenon in ischemic myocardium. Virchows Arch 1983; 399: 325-332.
18. Yanagisawa M Kurihara H Kimura S. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
19. Niccoli G Lanza GA Shaw S. et al. Endothelin-1 and acute myocardial infarction: A no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006; 27: 1793-1798.
20. Ohlstein EH Arleth AJ Storer B. et al. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol 1998; 30: 167-173.